Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Eric Laille"'
Autor:
Nicolas Boissel, Patrice Chevallier, Kevin Curran, Gary Schiller, Hongtau Liu, Richard Larson, Daniel J. Deangelo, Jean-Baptiste Mear, Stephan Grupp, André Baruchel, Marina Konopleva, Alexandra Lacroce, Caroline Roudet, Ana Korngold, Katie Newhall, Eric Laille, Daniel Lee, Mark Frattini, Nitin Jain
Publikováno v:
HemaSphere, Vol 7, p e323373f (2023)
Externí odkaz:
https://doaj.org/article/d1b05a402662471f84abd44475913a2c
Autor:
Eric Laille, Tao Shi, Guillermo Garcia-Manero, Christopher R Cogle, Steven D Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J MacBeth
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135520 (2015)
CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this two-part study, a 7-day CC-486 dosing schedule showed clinical activity, was generally well t
Externí odkaz:
https://doaj.org/article/381043cb23d64b4bb4c5ab92a2004ee8
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Mean paclitaxel plasma concentrations following nab-paclitaxel administration alone or with CC-486 in part 1 arm B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eefdbd5b10a450837b99a92154c80bc
https://doi.org/10.1158/1078-0432.22469373
https://doi.org/10.1158/1078-0432.22469373
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Table S1. CC-486 Plus Carboplatin Dose Levels in Part 1 Arm A Table S2. CC-486 Plus nab-Paclitaxel Dose Levels in Part 1 Arm B Table S3. CC-486 Dose Levels in Part 1 Arm C Table S4. Number of Patients With Treatment Emergent Adverse Events for Part 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91814ef9e8949aae1e95bacbfce8808a
https://doi.org/10.1158/1078-0432.22469364
https://doi.org/10.1158/1078-0432.22469364
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Mean total carboplatin plasma concentration following carboplatin administration alone or with CC-486 in part 1 arm A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::682bf5cb413b4e7a057f3bc39464dbea
https://doi.org/10.1158/1078-0432.22469376
https://doi.org/10.1158/1078-0432.22469376
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Pharmacodynamic Assessments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5a6bc2fae21e4f0b16b715a823c0ad
https://doi.org/10.1158/1078-0432.22469367.v1
https://doi.org/10.1158/1078-0432.22469367.v1
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Correlation analysis between pharmacodynamic and pharmacokinetic findings in part 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50f70f4ed0a92b75190f034aea2886e5
https://doi.org/10.1158/1078-0432.22469370.v1
https://doi.org/10.1158/1078-0432.22469370.v1
Autor:
Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Purpose: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe263d5c1a31e04f57ce2ef635de4d3
https://doi.org/10.1158/1078-0432.c.6527238.v1
https://doi.org/10.1158/1078-0432.c.6527238.v1
Autor:
Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Publikováno v:
Scientia
Enasidenib; Conventional care Enasidenib; Atenció convencional Enasidenib; Atención convencional This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3715a5d50e378580e2588f9f261b90de
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
Autor:
Stéphane, de Botton, Pau, Montesinos, Andre, Schuh, Cristina, Papayannidis, Paresh, Vyas, Andrew H, Wei, Hans Beier, Ommen, Sergey, Semochkin, Hee-Je, Kim, Richard A, Larson, Jamie, Koprivnikar, Olga, Frankfurt, Felicitas R, Thol, Jörg, Chromik, Jenny L, Byrne, Arnaud, Pigneux, Xavier, Thomas, Olga, Salamero, María-Belén, Vidriales, Vadim A, Doronin, Hartmut, Döhner, Amir T, Fathi, Eric, Laille, Xin, Yu, Maroof, Hasan, Patricia, Martín-Regueira, Courtney D, DiNardo
Publikováno v:
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 inhibitor, with conventional care regimens (CCR) in patients aged =60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f5721a519b6f1e60c6aafec14ec22139
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16620